FIG. 1.
Systemic manifestation of virus-induced disease in VV-WR-infected mice is significantly inhibited by treatment with ST-246. Seven-week-old BALB/c mice were challenged with a high dose (1.2 × 106 PFU) of VV-WR by the i.n. (A and B), DS (C and D), i.v. (E and F), s.c. (G and H), or i.p. (I and J) route and treated by oral gavage with vehicle (A, C, E, G, and I) or 100 mg/kg of ST-246 (B, D, F, H, and J) once daily. Pictures were taken on day 6 (i.n.) or day 9 (DS, i.v., s.c., and i.p.) postinfection, at which time disease symptoms were more pronounced. Systemic disease symptoms are clearly evident by signs of fur ruffling, weight loss, and/or hunching (first panel), satellite lesion formation on tails (indicated by arrows in the second panel), and conjunctivitis in the eye (third panel). The pictures shown represent one of two to three mice/group that were alive at the time of photography.